Company Overview

Update
Founded:
1929
Headquarters:
Boulogne-billancourt
Categories:
Biotechnology

Ipsen S.A. engages in the research, development, manufacture, and sale of pharmaceutical products worldwide. The company markets

Description

Update

Ipsen S.A. engages in the research, development, manufacture, and sale of pharmaceutical products worldwide. The company markets approximately 20 drugs. It offers pharmaceutical products targeting oncology, endocrinology, and neuromuscular disorders, as well as gastroenterology, cardiovascular, and cognitive disorders. Products The company’s products include: Decapeptyl is a peptide formulation for injection used to treat advanced prostate cancer. Somatuline and Somatuline Autogel is a sustained-release formulations for injection of a somatostatin analogue peptide for treating acromegaly. NutropinAq is a liquid formulation for daily use of recombinant human growth hormone used in the treatment of growth failures. Increlex is a recombinant human Insulin-like Growth-Factor-1 for normal growth of bones. Dysport acts to block acetylcholine release for the treatment of motor disorders and various forms of muscular spasticity,... See More

Investments (4)

Update

Acquisitions (3)

Update

Offices/Locations (1)

Update
  • Office

    65 Quai Georges Gorse

    Boulogne-billancourt, 92100

    FRA